These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 35044839)

  • 61. Comparison of radioiodine utilization in adolescent and young adult and older thyroid cancer patients.
    Goldfarb M; Sener SF
    Endocr Pract; 2014 May; 20(5):405-11. PubMed ID: 24326000
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.
    Mo X; Zhou M; Yan H; Chen X; Wang Y
    Cancer Med; 2021 Aug; 10(15):5338-5346. PubMed ID: 34189859
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association between postoperative radiotherapy for young-onset nonsmall cell lung cancer and risk of second primary malignancies: comparative study.
    Li Z; Guo M; Liu L; Deng S
    Int J Surg; 2024 Aug; 110(8):4617-4623. PubMed ID: 38716897
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
    Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
    Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
    Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
    Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
    Gosain R; Alexander JS; Gill A; Perez C
    Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
    Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
    Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
    [No Abstract]   [Full Text] [Related]  

  • 68. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
    James DL; Ryan ÉJ; Davey MG; Quinn AJ; Heath DP; Garry SJ; Boland MR; Young O; Lowery AJ; Kerin MJ
    JAMA Otolaryngol Head Neck Surg; 2021 Jun; 147(6):544-552. PubMed ID: 33792650
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables.
    Gandhi S; Abhyankar A; Basu S
    Nucl Med Commun; 2014 Feb; 35(2):205-9. PubMed ID: 24217429
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Radioactive Iodine in Differentiated Thyroid Carcinoma: A Systematic AGREE II Clinical Practice Guideline Appraisal.
    Monos S; Fritz C; Harris J; Romeo D; Ng JJ; Xu K; Cooperberg B; Moreira A; Rajasekaran K
    Otolaryngol Head Neck Surg; 2024 Jan; 170(1):20-33. PubMed ID: 37694597
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
    Ho AL; Dedecjus M; Wirth LJ; Tuttle RM; Inabnet WB; Tennvall J; Vaisman F; Bastholt L; Gianoukakis AG; Rodien P; Paschke R; Elisei R; Viola D; So K; Carroll D; Hovey T; Thakre B; Fagin JA;
    J Clin Oncol; 2022 Jun; 40(17):1870-1878. PubMed ID: 35192411
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patient-Perceived Lack of Choice in Receipt of Radioactive Iodine for Treatment of Differentiated Thyroid Cancer.
    Wallner LP; Reyes-Gastelum D; Hamilton AS; Ward KC; Hawley ST; Haymart MR
    J Clin Oncol; 2019 Aug; 37(24):2152-2161. PubMed ID: 31283406
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
    Auttara-Atthakorn A; Sungmala J; Anothaisintawee T; Reutrakul S; Sriphrapradang C
    Front Endocrinol (Lausanne); 2022; 13():960265. PubMed ID: 36105397
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Influence of radioactive iodine therapy on liver function in patients with differentiated thyroid cancer.
    Wang S; Liang C; Zhao L; Meng Z; Zhang C; Jia Q; Tan J; Yang H; Liu X; Wang X
    Nucl Med Commun; 2018 Dec; 39(12):1113-1120. PubMed ID: 30247387
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Birth rates after radioactive iodine treatment for differentiated thyroid cancer.
    Anderson C; Engel SM; Weaver MA; Zevallos JP; Nichols HB
    Int J Cancer; 2017 Dec; 141(11):2291-2295. PubMed ID: 28791691
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
    Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
    Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Thyroid adenomas after solid cancer in childhood.
    Haddy N; El-Fayech C; Guibout C; Adjadj E; Thomas-Teinturier C; Oberlin O; Veres C; Pacquement H; Jackson A; Munzer M; N'Guyen TD; Bondiau PY; Berchery D; Laprie A; Bridier A; Lefkopoulos D; Schlumberger M; Rubino C; Diallo I; de Vathaire F
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e209-15. PubMed ID: 22672756
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Radioiodine refractory differentiated thyroid cancer.
    Jin Y; Van Nostrand D; Cheng L; Liu M; Chen L
    Crit Rev Oncol Hematol; 2018 May; 125():111-120. PubMed ID: 29650270
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Radiation treatment of patients with primary pediatric malignancies: risk of developing thyroid cancer as a secondary malignancy.
    Rose J; Wertheim BC; Guerrero MA
    Am J Surg; 2012 Dec; 204(6):881-6; discussion 886-7. PubMed ID: 23026382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.